论文部分内容阅读
胶质瘤是成人颅内最常见的恶性肿瘤,以手术切除为主,辅以放疗、化疗是目前治疗胶质瘤的主要手段。替莫唑胺(Temozolomide,TMZ)是临床一线胶质瘤化疗药物,但临床使用过程中,胶质瘤对TMZ的耐药影响了化疗效果,限制了其广泛使用。DNA损伤的修复是TMZ耐药的重要机制之一。DNA修复酶与胶质瘤TMZ耐药密切相关,文中对DNA修复酶和胶质瘤TMZ耐药性研究进行了综述。
Glioma is the most common intracranial malignant tumors in adults, with surgical excision, supplemented by radiotherapy, chemotherapy is the main means of treatment of glioma. Temozolomide (TMZ) is a first-line clinical glioma chemotherapeutic drug. However, the clinical application of glioma resistance to TMZ affects the chemotherapeutic effect and limits its widespread use. DNA damage repair is one of the important mechanisms of TMZ resistance. The DNA repair enzyme is closely related to the resistance of TMZ glioma. The research on the resistance of DNA repair enzyme and glioma TMZ are reviewed in this paper.